

# Pedro Dorado

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9144460/publications.pdf>

Version: 2024-02-01

91  
papers

2,280  
citations

186265

28  
h-index

243625

44  
g-index

96  
all docs

96  
docs citations

96  
times ranked

1808  
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence and factors associated with COVID-19 in 13 hemodialysis units. <i>International Urology and Nephrology</i> , 2022, 54, 715-716.	1.4	0
2	Frequency of CYP2C9 Promoter Variable Number Tandem Repeat Polymorphism in a Spanish Population: Linkage Disequilibrium with CYP2C9*3 Allele. <i>Journal of Personalized Medicine</i> , 2022, 12, 782.	2.5	0
3	Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population. <i>Pharmacogenomics Journal</i> , 2021, 21, 140-151.	2.0	12
4	Prevalence of foot disorders according to chronic kidney disease stage. <i>Journal of Renal Care</i> , 2021, 47, 17-26.	1.2	1
5	Relevance of <i>NR1H2</i> variants on carbamazepine therapy in Mexican Mestizos with epilepsy at a tertiary-care hospital. <i>Pharmacogenomics</i> , 2021, 22, 983-996.	1.3	0
6	Covid-19 in 40 dialysis facilities. A prospective multicenter cohort study in Spain. <i>Portuguese Journal of Nephrology &amp; Hypertension</i> , 2021, 35, .	0.1	0
7	Genomic Ancestry, <i>CYP2D6</i> , <i>CYP2C9</i> , and <i>CYP2C19</i> Among Latin Americans. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 257-268.	4.7	27
8	High prevalence of <i>CYP2D6</i> ultrarapid metabolizers in a mestizo Colombian population in relation to Hispanic mestizo populations. <i>Pharmacogenomics</i> , 2020, 21, 1227-1236.	1.3	0
9	Prevalence of Potential Drug-Drug Interaction Risk among Chronic Kidney Disease Patients in a Spanish Hospital. <i>Pharmaceutics</i> , 2020, 12, 713.	4.5	19
10	Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy. <i>Pharmacogenomics Journal</i> , 2020, 20, 845-856.	2.0	6
11	Interethnic Variability in <i>CYP2D6</i> , <i>CYP2C9</i> , and <i>CYP2C19</i> Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics. <i>OMICS A Journal of Integrative Biology</i> , 2018, 22, 575-588.	2.0	32
12	<i>SAT0693</i> ...Genetic polymorphisms and efficacy of methotrexate in rheumatoid arthritis. , 2018, , .		0
13	<i>AB1296</i> ...Genetic polymorphisms and methotrexate safety in rheumatoid arthritis. , 2018, , .		0
14	High frequency of <i>CYP2D6</i> ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina. <i>Pharmacogenomics Journal</i> , 2017, 17, 378-381.	2.0	7
15	Lessons from Cuba for Global Precision Medicine: <i>CYP2D6</i> Genotype Is Not a Robust Predictor of <i>CYP2D6</i> Ultrarapid Metabolism. <i>OMICS A Journal of Integrative Biology</i> , 2017, 21, 17-26.	2.0	20
16	Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers. <i>Pharmacogenomics</i> , 2016, 17, 1913-1930.	1.3	8
17	<i>CYP2C9</i> , <i>CYP2C19</i> , <i>ABCB1</i> genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy. <i>Pharmacogenomics Journal</i> , 2016, 16, 286-292.	2.0	22
18	Interethnic relationships of <i>CYP2D6</i> variants in native and Mestizo populations sharing the same ecosystem. <i>Pharmacogenomics</i> , 2015, 16, 703-712.	1.3	13

#	ARTICLE	IF	CITATIONS
19	CYP2D6 Polymorphism and Mental and Personality Disorders in Suicide Attempters. <i>Journal of Personality Disorders</i> , 2014, 28, 873-883.	1.4	6
20	Research Highlights: Novel CYP2C9 genetic polymorphisms and assessment of their impact on hydroxylation capacity. <i>Pharmacogenomics</i> , 2014, 15, 261-264.	1.3	1
21	CYP2D6 genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas. <i>Pharmacogenomics</i> , 2014, 15, 1859-1865.	1.3	13
22	Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain. <i>Pharmacogenomics Journal</i> , 2014, 14, 229-234.	2.0	31
23	Liver enzyme abnormalities during antipsychotic treatment: a case report of risperidone-associated hepatotoxicity. <i>Drug Metabolism and Drug Interactions</i> , 2014, 29, 123-126.	0.3	9
24	Relationship between the CYP2C9 IVS8-109A>T polymorphism and high losartan hydroxylation in healthy Ecuadorian volunteers. <i>Pharmacogenomics</i> , 2014, 15, 1417-1421.	1.3	15
25	Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6. <i>Pharmacogenomics Journal</i> , 2013, 13, 452-455.	2.0	12
26	Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations. <i>Molecular Biology Reports</i> , 2013, 40, 3187-3192.	2.3	18
27	Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms. <i>Pharmacogenomics Journal</i> , 2013, 13, 359-361.	2.0	33
28	Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico. <i>Pharmacogenomics Journal</i> , 2013, 13, 567-572.	2.0	22
29	PP143 "Impact of UGT1A4 genotype in the clinical response to lamotrigine in patients with epilepsy. <i>Clinical Therapeutics</i> , 2013, 35, e61.	2.5	0
30	PP148 "Influence of CYP2C9 IVS8-109A>T Polymorphism on Losartan Oxidation in Healthy Ecuadorians. <i>Clinical Therapeutics</i> , 2013, 35, e64-e65.	2.5	0
31	PP139 "Association of ABCB1, ABCC2, CYP2C9 and CYP2C19 polymorphism with phenytoin plasma concentrations. <i>Clinical Therapeutics</i> , 2013, 35, e59-e60.	2.5	0
32	PP157 "CYP2C9 Allele Frequencies Among Three Costa Rican Ethnic Groups Compared With Hispanic Populations. <i>Clinical Therapeutics</i> , 2013, 35, e67-e68.	2.5	0
33	Research Highlights. <i>Pharmacogenomics</i> , 2013, 14, 603-606.	1.3	0
34	MDR-1 genotypes and quetiapine pharmacokinetics in healthy volunteers. <i>Drug Metabolism and Drug Interactions</i> , 2013, 28, 163-166.	0.3	12
35	Evaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: the CEIBA cocktail. <i>Drug Metabolism and Drug Interactions</i> , 2013, 28, 135-146.	0.3	11
36	CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 627-630.	1.5	25

#	ARTICLE	IF	CITATIONS
37	CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients. <i>Molecular Psychiatry</i> , 2013, 18, 8-9.	7.9	46
38	Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. <i>Pharmacogenomics Journal</i> , 2013, 13, 197-204.	2.0	20
39	<i>CYP2D6</i> -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers. <i>Pharmacogenomics</i> , 2013, 14, 1973-1977.	1.3	23
40	<i>CYP2D6</i> and the severity of suicide attempts. <i>Pharmacogenomics</i> , 2012, 13, 179-184.	1.3	37
41	<i>CYP2D6</i> polymorphism in patients with eating disorders. <i>Pharmacogenomics Journal</i> , 2012, 12, 173-175.	2.0	25
42	High-performance liquid chromatography method using ultraviolet detection for the quantification of aripiprazole and dehydroaripiprazole in psychiatric patients. <i>Drug Metabolism and Drug Interactions</i> , 2012, 27, 165-70.	0.3	2
43	Losartan hydroxylation phenotype in an Ecuadorian population: influence of <i>CYP2C9</i> genetic polymorphism, habits and gender. <i>Pharmacogenomics</i> , 2012, 13, 1711-1717.	1.3	28
44	<i>CYP2D6</i> genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans. <i>Pharmacogenomics Journal</i> , 2012, 12, 176-183.	2.0	62
45	Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of <i>CYP2C9</i> hydroxylation phenotypes. <i>Drug Metabolism and Drug Interactions</i> , 2012, 27, 217-223.	0.3	8
46	<i>CYP2D6</i> genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 637-644.	1.9	27
47	Eating Disorder Symptoms and <i>CYP2D6</i> Variation in Cuban Healthy Females: A Report from the Ibero-American Network of Pharmacogenetics. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2012, 10, 288-292.	0.2	4
48	<i>CYP2C9</i> allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards. <i>Pharmacogenomics Journal</i> , 2011, 11, 108-112.	2.0	46
49	Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine. <i>Drug Metabolism and Drug Interactions</i> , 2011, 26, 5-12.	0.3	22
50	High risk of lifetime history of suicide attempts among <i>CYP2D6</i> ultrarapid metabolizers with eating disorders. <i>Molecular Psychiatry</i> , 2011, 16, 691-692.	7.9	45
51	ATA homozygosity in the IL-10 gene promoter is a risk factor for schizophrenia in Spanish females: a case control study. <i>BMC Medical Genetics</i> , 2011, 12, 81.	2.1	15
52	Research Highlights. <i>Pharmacogenomics</i> , 2011, 12, 311-313.	1.3	2
53	Pharmacogenomics and Personality: Role of <i>CYP2D6</i> and Implications for Psychopathology. <i>Advances in Biological Psychiatry</i> , 2010, , 30-45.	0.2	3
54	Influence of <i>CYP2D6</i> Deletion, Multiplication, -1584C>G, 31G>A and 2988G>A Gene Polymorphisms on Dextromethorphan Metabolism among Mexican Tepehuanos and Mestizos. <i>Pharmacology</i> , 2010, 86, 30-36.	2.2	32

#	ARTICLE	IF	CITATIONS
55	Evaluating a newly developed pharmacogenetic array: screening in a Spanish population. <i>Pharmacogenomics</i> , 2010, 11, 1619-1625.	1.3	12
56	Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. <i>Pharmacogenomics</i> , 2009, 10, 17-28.	1.3	65
57	Development of a new genotyping assay for detection of the <i>BDNF</i> Val66Met polymorphism using melting-curve analysis. <i>Pharmacogenomics</i> , 2009, 10, 989-995.	1.3	6
58	Relation between <i>CYP2D6</i> genotype, personality, neurocognition and overall psychopathology in healthy volunteers. <i>Pharmacogenomics</i> , 2009, 10, 1111-1120.	1.3	49
59	Relevance of <i>CYP2D6</i>-1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients. <i>Pharmacogenomics</i> , 2009, 10, 1083-1089.	1.3	17
60	Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 967-970.	1.9	30
61	Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. <i>Pharmacogenomics</i> , 2008, 9, 833-840.	1.3	66
62	Aripiprazole-Induced Parkinsonism and Its Association With Dopamine and Serotonin Receptor Polymorphisms. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 352-353.	1.4	9
63	Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 9-19.	3.3	17
64	Low frequency of CYP2D6 poor metabolizers among schizophrenia patients. <i>Pharmacogenomics Journal</i> , 2007, 7, 408-410.	2.0	37
65	Association between T102C and A<sup>1438G</sup> polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 835-8.	2.3	23
66	<i>CYP2D6</i> polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits. <i>Pharmacogenomics</i> , 2007, 8, 1597-1608.	1.3	58
67	Increased risk for major depression associated with the short allele of the serotonin transporter promoter region (5-HTTLPR-S) and the CYP2C9*3 allele. <i>Fundamental and Clinical Pharmacology</i> , 2007, 21, 451-453.	1.9	33
68	No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 527-528.	1.9	3
69	Clinical Implications of CYP2D6 Genetic Polymorphism During Treatment with Antipsychotic Drugs. <i>Current Drug Targets</i> , 2006, 7, 1671-1680.	2.1	24
70	CYP2C9 and clinical response to antidepressant drugs in Mexican-Americans. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, P24-P24.	4.7	1
71	Reduced completed suicide rate in Hungary from 1990 to 2001: Relation to suicide methods. <i>Journal of Affective Disorders</i> , 2005, 88, 235-238.	4.1	22
72	Development of a PCR-based strategy for <i>CYP2D6</i> genotyping including gene multiplication of worldwide potential use. <i>BioTechniques</i> , 2005, 39, S571-S574.	1.8	68

#	ARTICLE	IF	CITATIONS
73	Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship. <i>Clinical Chemistry and Laboratory Medicine</i> , 2005, 43, 275-9.	2.3	13
74	Relationship between Haloperidol Plasma Concentration, Debrisoquine Metabolic Ratio, CYP2D6 and CYP2C9 Genotypes in Psychiatric Patients. <i>Pharmacopsychiatry</i> , 2004, 37, 69-73.	3.3	18
75	The Role of Cytochrome P450 Enzymes in the Metabolism of Risperidone and Its Clinical Relevance for Drug Interactions. <i>Current Drug Targets</i> , 2004, 5, 573-579.	2.1	52
76	Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards. <i>Pharmacogenomics Journal</i> , 2004, 4, 403-406.	2.0	62
77	Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. <i>European Journal of Clinical Pharmacology</i> , 2004, 59, 869-873.	1.9	69
78	QTc Interval, CYP2D6 and CYP2C9 Genotypes and Risperidone Plasma Concentrations. <i>Journal of Psychopharmacology</i> , 2004, 18, 189-193.	4.0	69
79	Reproducibility over time of the urinary diclofenac/4- $\beta$ -OH diclofenac ratio among different CYP2C9 genotypes. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2003, 28, 213-215.	1.6	2
80	Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 45-50.	1.9	46
81	CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 221-225.	1.9	95
82	Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 783, 25-31.	2.3	52
83	Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 783, 213-219.	2.3	40
84	CYP2C9 gene and susceptibility to major depressive disorder. <i>Pharmacogenomics Journal</i> , 2003, 3, 300-302.	2.0	27
85	Analysis of diclofenac and its metabolites by high-performance liquid chromatography: relevance of CYP2C9 genotypes in diclofenac urinary metabolic ratios. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 789, 437-442.	2.3	20
86	Relationship between Risperidone and 9-hydroxy-risperidone Plasma Concentrations and CYP2D6 Enzyme Activity in Psychiatric Patients. <i>Pharmacopsychiatry</i> , 2002, 35, 231-234.	3.3	37
87	QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. <i>Journal of Psychopharmacology</i> , 2002, 16, 361-364.	4.0	58
88	QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 223-224.	1.9	18
89	Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 89-98.	4.7	164
90	Effect of Thioridazine Dosage on the Debrisoquine Hydroxylation Phenotype in Psychiatric Patients With Different CYP2D6 Genotypes. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 616-620.	2.0	48

#	ARTICLE	IF	CITATIONS
91	<i>CYP2D6</i> Polymorphism and Mental and Personality Disorders in Suicide Attempters. Journal of Personality Disorders, 0, , 1-11.	1.4	4